denv-1-lvhc
Vaccineexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2015 (NCT02372175)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Dengue virusImmunity, active
Dengue virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- denv-1-lvhc
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05967455 | Phase 1 | Oct 30, 2023 | State University of New York, Syracuse, United States Army |
| NCT03869060 | Phase 1 | Feb 4, 2019 | Janssen Pharmaceutica NV, State University of New York, Syracuse, United States Army |
| NCT02372175 | Phase 1 | Oct 1, 2015 | State University of New York, Syracuse, United States Army |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| State University of New York, Syracuse | Academic/Hospital | 3 | 2 | 1 | 2015 |
| United States Army | Government | 3 | 1 | 1 | 2015 |
| Janssen Pharmaceutica NV | For profit | 1 | 0 | 1 | 2019 |
3 organizations
Page 1 / 1